H1 Launches Generative AI Tool
H1 has announced the launch of GenosAI, a new generative AI tool embedded into its clinical trial intelligence platform, Trial Landscape, to analyze and respond to complex inquiries.
Trial Landscape allows sponsors to identify new sites, centers of excellence, and investigators with diverse patients; evaluate site and PI patient recruitment strategies; and gauge competition across trials. With GenosAI, clinical operations, feasibility, and medical teams can access deep insights, speed up workflows, explore new types of data, improve efficiencies and reduce costs, and accelerate time to market.
Trial Landscape pulls insights from more than 490,000 trials, 25 million publications, 10 million healthcare providers (including those with diversity data), 240 million patients, and 11 billion global claims. Clients can also integrate their own data, such as historical trial performance and feasibility questionnaire responses. GenosAI pulls from this data and, using the power of natural language processing (NLP), deciphers and responds to advanced analytical queries in a ChatGPT-like experience. Users can pose questions like “Which sponsors are running the most promising trials in small cell prostate cancer?” or “What are the best sites for my phase 3 prostate cancer study?” and receive responses in seconds.
“GenosAI has the power to be a pharma company’s most impactful Large Language Model (LLM) tool,” said Ariel Katz, CEO and co-founder, H1 in a press release. “With GenosAI, we’ve combined the power of conversational AI with our unmatched breadth of healthcare data to give sponsors access to the best data and technology possible. We hope this will have a profound impact on clinical trial diversity and efficacy.”
GenosAI sits on H1’s global data platform that uses technologies ranging from machine learning (ML) to NLP to create a unified source of truth for healthcare data. Data privacy and security is ensured through Microsoft Azure’s Enterprise GPT-4. Additionally, Guardrails reduce hallucinations common in healthcare language models, and the Retrieval Augmented Generation (RAG) approach enriches the model with H1-specific data and knowledge.
Reference
H1 Boosts Flagship Clinical Trial Intelligence Platform with Generative AI to Accelerate Clinical Trials. (2023, October 5). H1.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
